Reports Q4 revenue $51.3M, consensus $27.97M.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RIGL:
- Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Rigel announces publication summarizing results from Phase 2 study of REZLIDHIA
- Rigel Pharmaceuticals: NCCN adds REZLIDHIA to clinical practice guidelines
- Rigel Pharmaceuticals sees Q4 revenue $51.3M, consensus $21.65M